AMGEN WINS EPO PATENT INTERFERENCE
AMGEN WINS EPO PATENT INTERFERENCE THOUSAND OAKS, Calif., Dec. 5 /PRNewswire/-- Amgen Inc.
(NASDAQ-NMS: AMGN) today confirmed that The Board of Patent Appeals and Interferences of the United States Patent and Trademark Office has rendered judgement in favor of Amgen in each of the three interferences regarding recombinant human erythropoietin.
The first interference dealt with the previously issued patent awarded to Amgen's Dr. Fu-Kuen Lin, U.S. Patent number 4,703,008. The claims of this patent include the DNA, vectors, and host cells required to produce recombinant human erythropoietin. The second and third interferences involved two other Amgen patent applications, one of which claims the process to produce recombinant human erythropoietin, and the second of which claims the recombinant human erythropoietin product itself. As a result of these decisions, Amgen expects to receive patents for the process to produce recombinant human erythropoietin and the product itself. These patents will strengthen Amgen's patent portfolio protecting its EPOGEN (R) product. Amgen is a global pharmaceutical company developing human therapeutic products based on advances in cellular and molecular biology. The company is headquartered in Thousand Oaks. -0- 12/5/91 /CONTACT: Mark J. Brand, director, corporate communications, 805-499-5725, ext. 3028, or Lowell E. Sears, VP, Finance, 805-499- 5725 ext. 3055, both of Amgen/ (AMGN)
CH -- LA030 -- 9870 12/05/91 17:20 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Dec 5, 1991|
|Previous Article:||BELDING HEMINWAY NAMES ASSISTANT VICE PRESIDENTS|
|Next Article:||SIERRA REAL ESTATE EQUITY TRUST '84 ELECTION SURPRISES INCUMBENT DIRECTORS; BALLOTS TO BE INSPECTED|